Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
LIVERFASt is a highly sensitive and clinically useful diagnostic test for staging fibrosis in MASLD patients, including those with T2DM and has a higher Sn for detecting advanced fibrosis when compared with FIB-4.
Authors
- Marie Decraecker (ORCID: https://orcid.org/0000-0002-3304-2106)
- W Knapple (ORCID: https://orcid.org/0009-0007-4081-3304)
- Parvez Mantry (ORCID: https://orcid.org/0000-0003-4829-6931)
- Maxime Deregnaucourt
- Madhavi Rudraraju
- Meena B. Bansal (ORCID: https://orcid.org/0000-0002-7501-2191)
- Anita Kohli (ORCID: https://orcid.org/0000-0002-8848-9570)
- Sudha Kodali (ORCID: https://orcid.org/0000-0002-2816-9647)
- Ravi Sudhir Ravinuthala
- Rashmee Patil
- Ronald Quiambao
- Faïza Chermak
- Sanjaya K. Satapathy (ORCID: https://orcid.org/0000-0003-0153-2829)
- Humberto C. González (ORCID: https://orcid.org/0000-0003-3351-1846)
- Christopher Christensen (ORCID: https://orcid.org/0000-0002-8138-1217)
- William Alazawi
- Abdullah Mubarak
- Fernando E. Membreno
- H Sarles
- Rana Alkouri (ORCID: https://orcid.org/0000-0002-7376-4656)
- Quynh-An Phan
- MONA MUNTEANU
- Bal Raj Bhandari
- Medhi Sakka
- Naim Alkhouri
- Jean-Baptiste Hiriart
- Hany Elbeshbeshy
- Dominique Bonnefont-Rousselot
- Prasun Kumar Jalal
- Joseph Frank Kosinski
- Pamela Sylvestre
- Vicki McIntyre
- James Tonascia
- Matthew M. Yeh
- Stephen A. Harrison
- Reed B. Hogan II
- Juliette Foucher
- Imtiaz Alam
- Robert P. Morin Jr.
- Bradley S. Vander Veen
- Brigitte Le Bail
- Kimberly Mangee
- Arun J. Sanyal
- Victor Ankoma-Sey
- Gabriel H. Lee
Institutions
- Texas Tech University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Centre National de la Recherche Scientifique (FR)
- National Institutes of Health (US)
- Ardahan University (TR)
- iRobot (United States) (US)
- Henry Ford Health System (US)
- Inserm (FR)
- Queen Mary University of London (GB)
- Texas A&M University System (US)
- Baylor College of Medicine (US)
- Virginia Commonwealth University (US)
- Wayne State University (US)
- University of Washington (US)
- Université Paris Cité (FR)
- Tucson Medical Center (US)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Sorbonne Université (FR)
- Rio Grande Bible Institute (US)
- Arkansas Cardiology (US)
- Doctors Hospital at Renaissance (US)
- Infectious Disease Consultants (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Methodist Hospital (US)
- Pinnacle Clinical Research (US)
- Digestive Health Associates of Texas (US)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Pitié-Salpêtrière Hospital (FR)
- Quality Research (US)
- Texas Liver Institute (US)
- Texas Digestive Disease Consultants (US)
- Tallahassee Memorial HealthCare (US)
- Arizona Liver Health (US)
- Indian Medical Association (IN)
- Ohio Gastroenterology and Liver Institute (US)
- Premier Research Group (US)
- Saint Louis University (US)
- EcoHealth Alliance (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Gastrointestinal and Liver Diseases
- Published
- 2025-12-26
- DOI
- https://doi.org/10.15403/jgld-6432
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences
- Eisai
- Novo Nordisk
- Université de Bordeaux
- Ipsen
- Sirtex Medical
- Genentech
- National Institute of Diabetes and Digestive and Kidney Diseases